Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 112 matching trials from the live ClinicalTrials.gov search.
Completed Phase 4 Interventional Accepts healthy volunteers Results available

GLASSIA Infusion Rate Study

NCT01651351
Conditions
Alpha1-antitrypsin Deficiency, Healthy Volunteers
Interventions
Alpha1-proteinase inhibitor, Placebo: Human albumin 2.5%
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Active, not recruiting Not applicable Interventional

SELUTION 4 De Novo Small Vessel IDE Trial

NCT05946629
Conditions
Coronary Artery Disease
Interventions
PCI with SELUTION SLR DCB, PCI with FDA approved "-limus" DES
Device
Lead sponsor
M.A. Med Alliance S.A.
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
65
States / cities
Jonesboro, Arkansas • Chula Vista, California • Los Angeles, California + 54 more
Conditions
Stable Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CMX-2043, Placebo control
Drug
Lead sponsor
Ischemix, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Worcester, Massachusetts • Durham, North Carolina
Active, not recruiting Not applicable Interventional

LEADERS FREE II: BioFreedom™ Pivotal Study

NCT02843633
Conditions
Acute Coronary Syndrome, High Bleeding Risk
Interventions
BioFreedom™ Drug Coated Coronary Stent System, Antiplatelet Drug
Device · Drug
Lead sponsor
Biosensors Europe SA
Industry
Eligibility
Not listed
Enrollment
1,203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
39
States / cities
Huntsville, Alabama • Hot Springs, Arkansas • La Jolla, California + 34 more
Conditions
Coronary Artery Disease
Interventions
Percutaneous Coronary Intervention
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
34
States / cities
Little Rock, Arkansas • Glendale, California • Hartford, Connecticut + 30 more
Conditions
Non-ST Elevation Acute Coronary Syndrome
Interventions
ticagrelor, clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Jacksonville, Florida • Lake Mary, Florida • Macon, Georgia + 5 more
Conditions
Acute Myocardial Infarction, Coronary Artery Disease
Interventions
Physiology-guided NCL PCI, Angiography-guided NCL PCI
Procedure
Lead sponsor
Population Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
5,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Wichita, Kansas + 10 more
Recruiting Not applicable Interventional

FORWARD CAD IDE Study

NCT06662500
Conditions
Coronary Arterial Disease (CAD)
Interventions
Intravascular Lithotripsy
Device
Lead sponsor
Shockwave Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
28
States / cities
La Jolla, California • San Francisco, California • Littleton, Colorado + 19 more
Conditions
Coronary Artery Disease
Interventions
IMPLELLA LP 2.5, IABP Intra-aortic balloon pump
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
44
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 35 more
Conditions
Alpha1-Antitrypsin Deficiency
Interventions
Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human)
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Miami, Florida + 2 more
Completed Phase 4 Interventional Results available

EVOLVE Short DAPT Study

NCT02605447
Conditions
Coronary Artery Disease
Interventions
3 months of dual antiplatelet therapy (DAPT), SYNERGY Stent System
Drug · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
2,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
89
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 75 more
Conditions
Alpha 1-Antitrypsin Deficiency, Emphysema
Interventions
SAR447537
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more
Completed Not applicable Interventional Results available

The MASS COMM Post-Randomization Phase Cohort Study

NCT02072421
Conditions
Coronary Artery Disease
Interventions
PCI
Procedure
Lead sponsor
Baim Institute for Clinical Research
Other
Eligibility
18 Years and older
Enrollment
2,879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Brockton, Massachusetts • Framingham, Massachusetts • Lawrence, Massachusetts + 5 more
Conditions
Small Cell Lung Cancer
Interventions
Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Olaparib 300 mg BID, Olaparib matching placebo, Etoposide 100 mg/m^2, Platinum, investigator's choice, Standard Thoracic Radiotherapy, Prophylactic Cranial Irradiation (PCI)
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
35
States / cities
Chandler, Arizona • Loma Linda, California • Washington D.C., District of Columbia + 29 more
Conditions
Coronary Artery Disease (CAD), Coronary Calcification, Coronary Calcified Disease, Coronary Calcified Nodules
Interventions
Shockwave C2 Aero Coronary IVL System
Device
Lead sponsor
OPCI Core Laboratories LLC
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
8
States / cities
Thousand Oaks, California • Detroit, Michigan • Neptune City, New Jersey + 5 more
Conditions
Acute Myocardial Infarction (AMI)
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease

NCT01731691
Conditions
HIV Disease
Interventions
α1 Proteinase Inhibitor, Placebos
Biological · Drug
Lead sponsor
Institute for Human Genetics and Biochemistry
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Completed No phase listed Observational

RUral dispaRities in prehospitAL STEMI

NCT04381260
Conditions
ST Elevation Myocardial Infarction, Cardiovascular Diseases
Interventions
No intervention, Interview, Survey
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
473 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Anterior Wall Acute Myocardial Infarction
Interventions
SuperSaturated Oxygen (SS02) Therapy
Device
Lead sponsor
TherOx
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Scottsdale, Arizona • Royal Oak, Michigan • Southfield, Michigan + 1 more
Completed Not applicable Interventional Results available

Comparing TR Band to Statseal in Conjunction With TR Band

NCT03028025
Conditions
Arterial Occlusion, Angina Pectoris, Cardiovascular Diseases, Atherosclerosis, Hematoma, Anticoagulant-Induced Bleeding, Coronary Artery Disease
Interventions
StatSeal, TR Band
Device
Lead sponsor
VA Long Beach Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Long Beach, California
Completed Phase 4 Interventional Results available

Kidney Damage in Patients With Moderate Fall in eGFR

NCT01136876
Conditions
Coronary Artery Stenosis
Interventions
Iopamidol, Iodixanol-320
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Springfield, Illinois • New Brunswick, New Jersey • Teaneck, New Jersey
Conditions
Myocardial Infarction
Interventions
Single Vessel Disease, Multi-vessel Disease, Culprit Vessel Only, Multi-vessel Disease, Complete Revascularization, Medtronic Resolute family of stents, Volcano based pressure wires Verrata, Verrata Plus and any subsequent marketed Volcano pressure wire technology, Terumo Glidesheath Slender, Terumo TR Band Radial Compression Device
Device · Procedure
Lead sponsor
David Kong, M.D.
Other
Eligibility
60 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
AMI
Interventions
Insulin Glargine (LANTUS), Insulin Glulisine (Apidra), Standard Therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Ibrutinib, Laboratory Biomarker Analysis, Pegfilgrastim, Pharmacological Study, Prednisone, Rituximab, Vincristine Sulfate
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 64 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
19
States / cities
La Jolla, California • San Francisco, California • Miami, Florida + 12 more